Disappointing phase I results halt Novo's Dutch acquisition

Novo Nordisk has chosen not to acquire its collaboration partner from the Netherlands after disappointing phase I results for a potential drug for cardiovascular diseases were reported.

Dutch company Staten Biotechnology retains its independence as Novo Nordisk has decided not to exercise an option to acquire both the company and its lead candidate, STT-5058, the Danish pharmaceutical company reports in its financial report on Wednesday.

The two firms partnered up in 2018 to develop STT-5058, which is a monoclonal antibody that Staten Biotechnology inlicensed from Dutch-Belgian company Argenx, which is a collaborator of Leo Pharma.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs